Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

41
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
41
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.2K
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

16
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
16
Complement System01:27

Complement System

10.4K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
10.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relative frequencies of muscle specific kinase antibody myasthenia in 46 centres worldwide.

Brain : a journal of neurology·2026
Same author

Immunotherapy responsive startle with antibodies to voltage gated potassium channels.

BMJ case reports·2025
Same author

Subtype-specific atypical B cell profiles in myasthenia gravis reveal distinct immunopathological pathways.

Frontiers in immunology·2025
Same author

Evolution and significance of neuronal surface autoantibodies after Japanese encephalitis.

Journal of neuroimmunology·2025
Same author

GAD antibodies in neurological disease: a critical evaluation of the utility and treatment implications of GAD antibodies in clinical practice.

Journal of neurology·2025
Same author

A clinical perspective on muscle specific kinase antibody positive myasthenia gravis.

Frontiers in immunology·2024

Related Experiment Video

Updated: Apr 26, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K

Complement activation in patients with neuromyelitis optica.

Petra Nytrova1, Eliska Potlukova2, David Kemlink3

  • 1Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, General University Hospital, Charles University in Prague, Czech Republic; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Journal of Neuroimmunology
|August 12, 2014
PubMed
Summary
This summary is machine-generated.

Neuromyelitis optica (NMO) patients show elevated complement system components, specifically C3a and anti-C1q antibodies. These levels correlate with disease activity, indicating the alternative complement pathway

Keywords:
Aquaporin-4 IgGC1q antibodiesComplementNeuromyelitis optica

More Related Videos

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

13.4K
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

7.4K

Related Experiment Videos

Last Updated: Apr 26, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

13.4K
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

7.4K

Area of Science:

  • Neuroimmunology
  • Complement System Biology
  • Autoimmune Neurology

Background:

  • The complement system's role in neuromyelitis optica (NMO) is established in experimental models.
  • Longitudinal analysis of complement components in NMO patients is limited.
  • Neuromyelitis optica is an autoimmune disorder affecting the central nervous system.

Purpose of the Study:

  • To longitudinally measure serum/plasma concentrations of complement components in NMO patients.
  • To compare complement levels between NMO patients, multiple sclerosis (MS) patients, and healthy controls.
  • To investigate the correlation between complement levels and disease parameters in NMO.

Main Methods:

  • Measurement of serum/plasma anti-C1q antibodies, C3a, C4a, and soluble C5b-9.
  • Analysis included patients with NMO, MS, and healthy individuals.
  • Correlational analysis between complement markers and clinical data (disease activity, disability, AQP4-IgG).

Main Results:

  • NMO patients exhibited significantly higher levels of C3a and anti-C1q antibodies compared to healthy controls.
  • C3a levels demonstrated a positive correlation with disease activity and neurological disability in NMO patients.
  • C3a levels also correlated with aquaporin-4 IgG status in NMO patients.

Conclusions:

  • The alternative pathway of the complement system likely plays a role in NMO pathogenesis.
  • Elevated C3a and anti-C1q antibodies suggest complement system activation in NMO.
  • These findings support the potential efficacy of therapeutic complement inhibition strategies for NMO.